Utilizing the inherent allogeneic potential of γ-δT cells, scientists can develop off-the-shelf γ-δT products that bypass the need for HLA matching, dramatically simplifying logistics and accelerating patient access.
Targeted Drug Delivery for γ-δT Cell Therapy
Creative Biolabs provides specialized genetic engineering and targeted delivery system development services. We empower biotech and pharmaceutical clients to unlock the full anti-tumor potential of γ-δT cells, solving critical challenges in solid tumor therapy and allogeneic manufacturing for a superior commercial product.
What is Targeted Delivery?
In γ-δT cell therapy manufacturing, targeted delivery refers to the efficient and low-toxicity introduction of functionally enhancing genes into γ-δT cells in vitro. It focuses on two core principles. First, Highly Efficient Modification: providing the most efficient and gentlest gene delivery technology, often via optimized viral or non-viral vectors, for this difficult-to-transfect cell type. Second, Functional Integrity: ensuring the delivery process does not affect the natural MHC-independent recognition and potent cytotoxic functions of γ-δT cells, preserving their intrinsic advantages against immune evasion.
Applications for γ-δT Cell Therapy
Universal Anti-tumor Cell Therapy
Solid Tumor Targeted Enhancement
Genetic armoring enables the delivery of potent enhancing cytokine genes (such as IL-15 fusions) to maximize the killing activity and persistence of γ-δT cells within the highly suppressive solid tumor microenvironment (TME).
Cell Function and Homing Optimization
Delivery systems introduce chemokine receptors or metabolic reprogramming molecules to enhance the in vitro expansion, improve in vivo survival, and boost the tumor infiltration capacity of the therapeutic γ-δT cells for durable responses.
Fig.1 Hurdles impeding application of γδ T cells.1
Delivery Challenges of γ-δT Cell Therapy
γ-δT cells are present in a low proportion in peripheral blood. Achieving large-scale, high-quality in vitro expansion relies heavily on efficient molecular enhancement, such as delivering cytokine genes that combat T cell exhaustion.
What We Can Offer
We provide professional targeted delivery technology, focusing on solving the challenges of efficiency, expansion, and functional enhancement in γ-δT therapy manufacturing:
Breakthrough Cell Transfection
Targeting the unique characteristics of γ-δT cells, we offer optimized LNP/nanocarriers and customized mild non-viral transfection protocols. This proprietary approach achieves both high viability and high efficiency in functional gene delivery, minimizing cell stress.
Cell Expansion & Enhanced Activation (Cytokine Armoring)
We enable the synergistic delivery of cytokine genes that promote γ-δT cell proliferation and combat cell exhaustion (such as the IL-15 gene payload). This significantly improves in vitro expansion yield and the functional quality of the final therapeutic product.
Universal Product Engineering
Our non-viral delivery solutions are highly scalable and cost-effective, supporting the superior engineering of allogeneic γ-δT cells and accelerating the industrial production of universal, off-the-shelf products.
Homing Molecule Delivery
We specialize in delivering chemokine receptor mRNA or other homing peptides to enhance the response of γ-δT cells to the tumor microenvironment, improving tumor invasion and overall treatment efficacy.
Why Choose Us?
Proprietary Vector Technology
We utilize advanced vectors, including LNP, ensuring industry-leading transduction efficiency for challenging γ-δT cells.
Dual-Recognition Systems
Our specialized payload engineering creates systems that target both Tumor-Associated Antigens (TAA) and Phosphoantigens (pAg), maximizing tumor coverage and efficacy.
Allogeneic Focus
We accelerate the development of allogeneic, off-the-shelf products, maximizing commercial scalability and simplifying patient logistics.
Workflow
Unlock the full therapeutic power of γ-δT cells. Contact us today to schedule an in-depth review of our targeted delivery platform and explore strategic co-development opportunities.
Reference
- Wang, Chelsia Qiuxia, Pei Yu Lim, and Andy Hee-Meng Tan. "Gamma/delta T cells as cellular vehicles for anti-tumor immunity." Frontiers in Immunology 14 (2024): 1282758. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1282758.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
